Prudent Man Advisors LLC Has $772,000 Holdings in Vertex Pharmaceuticals Incorporated $VRTX

Prudent Man Advisors LLC increased its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 27.7% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,735 shares of the pharmaceutical company’s stock after acquiring an additional 376 shares during the quarter. Prudent Man Advisors LLC’s holdings in Vertex Pharmaceuticals were worth $772,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. Activest Wealth Management acquired a new stake in shares of Vertex Pharmaceuticals during the first quarter valued at approximately $25,000. Clal Insurance Enterprises Holdings Ltd raised its holdings in shares of Vertex Pharmaceuticals by 450.0% during the first quarter. Clal Insurance Enterprises Holdings Ltd now owns 55 shares of the pharmaceutical company’s stock valued at $27,000 after acquiring an additional 45 shares during the period. Flaharty Asset Management LLC acquired a new stake in shares of Vertex Pharmaceuticals during the first quarter valued at approximately $32,000. American National Bank & Trust raised its holdings in shares of Vertex Pharmaceuticals by 515.4% during the second quarter. American National Bank & Trust now owns 80 shares of the pharmaceutical company’s stock valued at $36,000 after acquiring an additional 67 shares during the period. Finally, University of Texas Texas AM Investment Management Co. acquired a new stake in shares of Vertex Pharmaceuticals during the first quarter valued at approximately $46,000. Institutional investors and hedge funds own 90.96% of the company’s stock.

Vertex Pharmaceuticals Stock Down 0.3%

VRTX stock opened at $421.39 on Friday. The company has a market capitalization of $108.04 billion, a price-to-earnings ratio of 30.12 and a beta of 0.43. Vertex Pharmaceuticals Incorporated has a 12 month low of $362.50 and a 12 month high of $519.88. The firm has a 50 day moving average of $398.96 and a two-hundred day moving average of $434.61.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its earnings results on Monday, August 4th. The pharmaceutical company reported $4.52 EPS for the quarter, topping the consensus estimate of $4.24 by $0.28. The company had revenue of $2.94 billion during the quarter, compared to the consensus estimate of $2.90 billion. Vertex Pharmaceuticals had a net margin of 31.86% and a return on equity of 23.91%. The company’s revenue for the quarter was up 11.3% compared to the same quarter last year. During the same period in the previous year, the firm posted ($12.83) earnings per share. Vertex Pharmaceuticals has set its FY 2025 guidance at EPS. On average, research analysts expect that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on VRTX shares. Raymond James Financial assumed coverage on shares of Vertex Pharmaceuticals in a report on Tuesday, September 2nd. They set a “market perform” rating on the stock. Cantor Fitzgerald dropped their price objective on shares of Vertex Pharmaceuticals from $535.00 to $485.00 and set an “overweight” rating on the stock in a research note on Tuesday, August 5th. Truist Financial set a $490.00 price objective on shares of Vertex Pharmaceuticals and gave the company a “buy” rating in a research note on Tuesday, August 5th. Weiss Ratings reiterated a “hold (c+)” rating on shares of Vertex Pharmaceuticals in a research note on Friday. Finally, BMO Capital Markets set a $530.00 price objective on shares of Vertex Pharmaceuticals and gave the company an “outperform” rating in a research note on Tuesday, August 5th. One investment analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and twelve have assigned a Hold rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $494.38.

Insider Buying and Selling

In other Vertex Pharmaceuticals news, Director Bruce I. Sachs bought 5,000 shares of the firm’s stock in a transaction on Wednesday, August 6th. The stock was bought at an average cost of $389.68 per share, with a total value of $1,948,400.00. Following the completion of the transaction, the director directly owned 45,000 shares of the company’s stock, valued at approximately $17,535,600. The trade was a 12.50% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 0.20% of the stock is owned by corporate insiders.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.